BRAK LABS Peptide research, plainly written

documented protocols

CJC-1295 with DAC: what is documented about dosing

The published studies state what they gave. Those figures are reported here as what a study did, which is all they are.

Last Reviewed Editorial policy Methodology

What follows is what published studies administered, reported as that and nothing else. This site publishes no dosing guidance for any compound.

Not medical advice

This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.

Reviewed against editorial standards Updated

What this page reports, and what it does not

We report what has been documented. We do not prescribe what should be done.

Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.

No trial established an amount of CJC-1295 with DAC for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.

Commonly cited protocols (extrapolated, not validated)

What published studies gave, in which species and by which route, and what circulates elsewhere. The source class is named on every row, and none of it is a clinical protocol
StudyWhat was givenFrequencyDurationNotes
Ascending-dose trials, 2006Amounts stated per kilogram of body weight in the source paperSingle, then weekly or every two weeks28 and 49 daysHealthy adults. Outcome measures were hormone concentrations, not results
Pulse pattern study, 2006Two amounts per kilogram, stated in the source paperSingle injectionSampled one week laterNo significant difference in response between the two amounts tested
Serum protein study, 2009As stated in the source paperSingle injectionSampled one week later11 participants
The terminated phase 2A low dose arm and a high dose arm, neither stated in the registry recordNot stated in the record12 weeks plannedTerminated with no reason given and no results posted
Any use for body composition or recoveryNothing documentedNothing documentedNothing documentedNo study has measured this compound against any such outcome

A long half-life is a pharmacokinetic property, not a schedule. Community sources build schedules out of the published half-life by arithmetic, and arithmetic on a half-life cannot establish how often anything should be given, because the relationship between concentration and effect for this compound has never been measured against an effect.

The one study that compared two different amounts head to head found no significant difference between them in growth hormone or IGF-1 response. That is the only comparative dose information that exists for this compound in a person.

Commonly cited protocols (extrapolated, not validated) circulate widely for this compound, including in a peer-reviewed 2026 review that documents them as a clinical phenomenon rather than endorsing them. This site does not reproduce them as guidance.

Nothing here is a dosing recommendation. Talk to a licensed clinician about anything concerning your health.

Our takeThe figures in the published studies are study parameters. The one comparison of two amounts found no difference between them, and no study has ever related an amount of this compound to an outcome.,Talk to a licensed clinician about anything concerning your health.

Main routes people compare

Injection under the skin

The route used in every published study of this compound and the route the half-life describes. FDA's compounding assessment cites immunogenicity risk for certain routes of administration, which is a statement about the agency's information rather than about any route being established as safe.

In a blend with a second compound

The commonest way both CJC-1295 products are sold is combined with a growth hormone secretagogue, most often ipamorelin. No published study of this compound tested it in a blend, so nothing on this page describes what a blend does.

What is said about cycle length and timing

No cycle length appears in the published record for this compound. The trials ran 28 and 49 days for pharmacology and the terminated trial planned 12 weeks, and none of those was designed to establish a duration of use.

Talk to a licensed clinician about anything concerning your health.

What has been measured about safety

A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about CJC-1295 with DAC, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.

Frequently asked questions

How long does one injection last?

The estimated half-life of the compound is 5.8 to 8.1 days. A single injection raised mean growth hormone for six days or more and mean IGF-1 for nine to eleven days in the published trials.

Does a larger amount do more?

The one study that compared two amounts head to head reported no significant difference between them in growth hormone or IGF-1 response.

Is there an established schedule?

No. Schedules in circulation are built by arithmetic from the published half-life. That arithmetic cannot establish a schedule, because no study has related an amount or a frequency of this compound to any outcome.

What did the trials actually give?

Amounts stated per kilogram of body weight, as single injections and then weekly or every two weeks, over 28 and 49 days. This site reports those as study parameters and gives no guidance.

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683 DOI 10.1210/jc.2005-1536
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PMID 17018654 DOI 10.1210/jc.2006-1702
  3. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009. PMID 19386527 DOI 10.1016/j.ghir.2009.03.001
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. PMID 16822960 DOI 10.1152/ajpendo.00201.2006
  5. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016. PMID 26771670 DOI 10.3109/10826084.2015.1082595
  6. Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016. PMID 26879649 DOI 10.1007/s00216-016-9377-3
  7. Timms M, Ganio K, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019. PMID 30938069 DOI 10.1002/dta.2599
  8. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026. PMID 42395176 DOI 10.3389/fendo.2026.1822475
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID 41966639 DOI 10.1007/s40279-026-02437-0
  10. Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026. PMID 42160466 DOI 10.2106/JBJS.RVW.26.00027
  11. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018. PMID 30029448 DOI 10.1016/j.talanta.2018.06.023
  12. ClinicalTrials.gov. NCT00267527, study ID GH100-013: a multicenter, randomized, placebo-controlled, double-blind phase 2 study to evaluate the efficacy and safety of CJC 1295 administered for 12 weeks in HIV infected patients with HIV associated visceral obesity, sponsored by ConjuChem, with a listed enrolment of 120 randomized to low dose, high dose or placebo and a 6 week follow-up. Listed start December 2005, listed completion September 2006. Recorded as TERMINATED with the whyStopped field EMPTY, no results posted, no primary outcome measures listed, and no update to the record since 12 October 2006. The record names the intervention only as CJC 1295 and gives no description, so which variant it used is not established. Read through the v2 API on 23 August 2026. ClinicalTrials.gov. 2026. NCT00267527
  13. ClinicalTrials.gov. Registry sweep for CJC-1295, CJC 1295, CJC1295, modified GRF 1-29, drug affinity complex GHRH, tetrasubstituted GHRH analog and ConjuChem GHRH, plus a sponsor query for ConjuChem, run through the v2 API on 23 August 2026. Exactly one record names the compound in its interventions: NCT00267527. No registration exists under any name for the version sold without the albumin linker. ClinicalTrials.gov. 2026. ClinicalTrials.gov
  14. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. The category 2 table carries the row CJC-1295, reading in full: compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization; FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction; available clinical data are limited. Page content current as of 22 April 2026, fetched with a browser user agent and read on 23 August 2026. FDA human drug compounding. 2026. FDA category 2 list
  15. World Anti-Doping Agency. The 2026 Prohibited List, international standard, effective 1 January 2026. Section S2.2.4 names CJC-1295 on the list's own face, alongside ipamorelin, ibutamoren, examorelin, GHRP-2, GHRP-6, sermorelin and tesamorelin. S2 substances are prohibited at all times. Retrieved by hand and read back on 9 August 2026; the URL serves zero bytes to automation and is ledgered in tools/unverified-sources.json. World Anti-Doping Agency. 2026. WADA 2026 Prohibited List
  16. US Food and Drug Administration. Drugs@FDA approved drug products, queried through the openFDA drugsfda endpoint on 23 August 2026 for CJC-1295 and CJC 1295 across the generic name and brand name fields. Both queries returned NOT_FOUND: there is no approved US application under either spelling. openFDA. 2026. openFDA drugsfda